Cargando…

Novel Somatostatin Receptor Ligands Therapies for Acromegaly

Surgery is considered the treatment of choice in acromegaly, but patients with persistent disease after surgery or in whom surgery cannot be considered require medical therapy. Somatostatin receptor ligands (SRLs) octreotide (OCT), lanreotide, and the more recently approved pasireotide, characterize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paragliola, Rosa Maria, Salvatori, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845985/ https://www.ncbi.nlm.nih.gov/pubmed/29563895 http://dx.doi.org/10.3389/fendo.2018.00078

Ejemplares similares

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
por: Nista, Federica, et al.
Publicado: (2021)

Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer
por: Dharan, Shalini Sree, et al.
Publicado: (2017)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)
por: Brunetti, Alessandro, et al.
Publicado: (2022)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

The Endothelium in Acromegaly
por: Maffei, Pietro, et al.
Publicado: (2019)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
por: Hu, Yuheng, et al.
Publicado: (2021)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
por: Prencipe, N., et al.
Publicado: (2020)

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)

Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
por: Rass, Lena, et al.
Publicado: (2021)

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
por: van Albada, Mirjam E., et al.
Publicado: (2022)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

The acromegaly lipodystrophy
por: Freda, Pamela U.
Publicado: (2022)

Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2019)

Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?
por: Liu, Winnie, et al.
Publicado: (2022)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy
por: Bona, C., et al.
Publicado: (2022)

Colonic Cancer and Acromegaly
por: Dworakowska, Dorota, et al.
Publicado: (2019)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

Left Heart Dysfunction in Acromegaly Revealed by Novel Echocardiographic Methods
por: Uziȩbło-Życzkowska, Beata, et al.
Publicado: (2020)

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
por: Geer, Eliza B., et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ugr0oriittmgsp5npql073hkjb